On November 28, 2022 Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, reported the U.S. Patent Office has issued a key patent covering the company’s Shielded-Cell & Immunotherapy Pairs (SCIP) platform (Press release, Cimeio Therapeutics, NOV 28, 2022, https://www.cimeio.com/2022/11/28/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform/?utm_source=rss&utm_medium=rss&utm_campaign=cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform [SID1234624489]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
U.S. Patent No. 11,499,168 covers a method for in vivo selective depletion of edited primary hematopoietic cells or non-edited primary hematopoietic cells. This method was first discovered and developed in the lab of company founder Lukas Jeker, M.D., Ph.D., at the University of Basel, and is exclusively licensed to Cimeio.
"This comprehensive intellectual property provides broad protection for our platform," said Cimeio CEO Thomas Fuchs. "We believe this patent, along with those we’ve filed for our target antigen and immunotherapy portfolio, cements us as a leader in the emerging field of cell shielding and will enable the broad development of our SCIP platform."
Cimeio uses genome editing to insert novel protein variants into hematopoietic stem cells or other types of cells, allowing the cells to maintain their function while making them resistant to paired immunotherapy depletion. Cimeio’s platform has effectively shielded cells from depletion mediated by antibodies, T-cell engagers, ADCs, and CAR-T cells in preclinical studies.
The company is advancing its first programs towards clinical development for genetic and malignant hematologic diseases. As previously disclosed, two posters for the company’s pipeline programs will be presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) meeting in December 2022 in New Orleans.